Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 14 |
| List of Tables | 13 | 2 |
| List of Figures | 15 | 1 |
| Introduction | 16 | 1 |
| Global Markets Direct Report Coverage | 16 | 1 |
| Mantle Cell Lymphoma Overview | 17 | 1 |
| Therapeutics Development | 18 | 2 |
| Pipeline Products for Mantle Cell Lymphoma Overview | 18 | 1 |
| Pipeline Products for Mantle Cell Lymphoma Comparative Analysis | 19 | 1 |
| Mantle Cell Lymphoma Therapeutics under Development by Companies | 20 | 4 |
| Mantle Cell Lymphoma Therapeutics under Investigation by Universities/Institutes | 24 | 1 |
| Mantle Cell Lymphoma Pipeline Products Glance | 25 | 3 |
| Late Stage Products | 25 | 1 |
| Clinical Stage Products | 26 | 1 |
| Early Stage Products | 27 | 1 |
| Mantle Cell Lymphoma Products under Development by Companies | 28 | 5 |
| Mantle Cell Lymphoma Products under Investigation by Universities/Institutes | 33 | 1 |
| Mantle Cell Lymphoma Companies Involved in Therapeutics Development | 34 | 48 |
| AB Science SA | 34 | 1 |
| AbbVie Inc | 35 | 1 |
| Acetylon Pharmaceuticals, Inc. | 36 | 1 |
| Actinium Pharmaceuticals, Inc. | 37 | 1 |
| Affimed GmbH | 38 | 1 |
| Amgen Inc. | 39 | 1 |
| Asana BioSciences, LLC | 40 | 1 |
| Astellas Pharma Inc. | 41 | 1 |
| Astex Pharmaceuticals, Inc. | 42 | 1 |
| Bayer AG | 43 | 1 |
| BeiGene, Ltd. | 44 | 1 |
| Bristol-Myers Squibb Company | 45 | 1 |
| Celgene Corporation | 46 | 1 |
| Cellular Biomedicine Group, Inc. | 47 | 1 |
| Eisai Co., Ltd. | 48 | 1 |
| Eli Lilly and Company | 49 | 1 |
| EpiZyme, Inc. | 50 | 1 |
| Gilead Sciences, Inc. | 51 | 1 |
| GlaxoSmithKline Plc | 52 | 1 |
| Hutchison MediPharma Limited | 53 | 1 |
| ImmunoGen, Inc. | 54 | 1 |
| Immunomedics, Inc. | 55 | 1 |
| Incyte Corporation | 56 | 1 |
| Inflection Biosciences Limited | 57 | 1 |
| Johnson &Johnson | 58 | 1 |
| Juno Therapeutics Inc. | 59 | 1 |
| Karyopharm Therapeutics, Inc. | 60 | 1 |
| Kite Pharma, Inc. | 61 | 1 |
| LFB S.A. | 62 | 1 |
| MacroGenics, Inc. | 63 | 1 |
| MedImmune, LLC | 64 | 1 |
| Merck &Co., Inc. | 65 | 1 |
| Merck KGaA | 66 | 1 |
| Millennium Pharmaceuticals Inc | 67 | 1 |
| MorphoSys AG | 68 | 1 |
| Nordic Nanovector ASA | 69 | 1 |
| Novartis AG | 70 | 1 |
| Onconova Therapeutics, Inc. | 71 | 1 |
| Oncternal Therapeutics, Inc. | 72 | 1 |
| Patrys Limited | 73 | 1 |
| Pharmacyclics, Inc. | 74 | 1 |
| Portola Pharmaceuticals, Inc. | 75 | 1 |
| Seattle Genetics, Inc. | 76 | 1 |
| Selvita S.A. | 77 | 1 |
| Stemline Therapeutics, Inc. | 78 | 1 |
| Takeda Pharmaceutical Company Limited | 79 | 1 |
| TG Therapeutics, Inc. | 80 | 1 |
| Vivolux AB | 81 | 1 |
| Mantle Cell Lymphoma Therapeutics Assessment | 82 | 16 |
| Assessment by Monotherapy Products | 82 | 1 |
| Assessment by Combination Products | 83 | 1 |
| Assessment by Target | 84 | 5 |
| Assessment by Mechanism of Action | 89 | 5 |
| Assessment by Route of Administration | 94 | 2 |
| Assessment by Molecule Type | 96 | 2 |
| Drug Profiles | 98 | 314 |
| (INCB-039110 + INCB-040093) Drug Profile | 98 | 1 |
| 13197 Drug Profile | 99 | 2 |
| AB-8779 Drug Profile | 101 | 1 |
| abexinostat hydrochloride Drug Profile | 102 | 3 |
| acalabrutinib Drug Profile | 105 | 3 |
| ACY-241 Drug Profile | 108 | 2 |
| ACY-775 Drug Profile | 110 | 1 |
| AFM-11 Drug Profile | 111 | 1 |
| alisertib Drug Profile | 112 | 5 |
| AMG-319 Drug Profile | 117 | 2 |
| ASN-002 Drug Profile | 119 | 1 |
| AT-7519 Drug Profile | 120 | 3 |
| avicin d Drug Profile | 123 | 1 |
| BC-8Y90 Drug Profile | 124 | 1 |
| bendamustine hydrochloride Drug Profile | 125 | 3 |
| Betalutin Drug Profile | 128 | 4 |
| BGB-3111 Drug Profile | 132 | 2 |
| BLyS-gel Drug Profile | 134 | 1 |
| BMS-986016 Drug Profile | 135 | 2 |
| buparlisib hydrochloride Drug Profile | 137 | 5 |
| carfilzomib Drug Profile | 142 | 12 |
| CBM-C19.1 Drug Profile | 154 | 1 |
| CBM-C20.1 Drug Profile | 155 | 2 |
| Cellular Immunotherapy for Oncology Drug Profile | 157 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 158 | 1 |
| cerdulatinib Drug Profile | 159 | 4 |
| copanlisib hydrochloride Drug Profile | 163 | 4 |
| daratumumab Drug Profile | 167 | 11 |
| denintuzumab mafodotin Drug Profile | 178 | 3 |
| durvalumab Drug Profile | 181 | 10 |
| E-7449 Drug Profile | 191 | 1 |
| entospletinib Drug Profile | 192 | 2 |
| epratuzumab Drug Profile | 194 | 7 |
| EPZ-015666 Drug Profile | 201 | 1 |
| HMPL-523 Drug Profile | 202 | 2 |
| IBL-301 Drug Profile | 204 | 2 |
| ibrutinib Drug Profile | 206 | 25 |
| IGN-002 Drug Profile | 231 | 2 |
| IMGN-529 Drug Profile | 233 | 2 |
| IMMU-114 Drug Profile | 235 | 2 |
| INA-01 Drug Profile | 237 | 1 |
| INCB-40093 Drug Profile | 238 | 1 |
| INCB-50465 Drug Profile | 239 | 1 |
| inebilizumab Drug Profile | 240 | 2 |
| inebilizumab + MEDI-0680 Drug Profile | 242 | 1 |
| Iomab-B Drug Profile | 243 | 5 |
| itacitinib adipate Drug Profile | 248 | 3 |
| ixazomib citrate Drug Profile | 251 | 9 |
| JCAR-014 Drug Profile | 260 | 3 |
| JCAR-015 Drug Profile | 263 | 5 |
| JCAR-017 Drug Profile | 268 | 3 |
| JNJ-64052781 Drug Profile | 271 | 2 |
| KTEC-19 Drug Profile | 273 | 7 |
| LAM-002A Drug Profile | 280 | 1 |
| M-7583 Drug Profile | 281 | 1 |
| Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections Drug Profile | 282 | 1 |
| Monoclonal Antibodies to Target ROR1 and CD3 for Oncology Drug Profile | 283 | 1 |
| MOR-208 Drug Profile | 284 | 5 |
| ON-123300 Drug Profile | 289 | 1 |
| ONC-201 Drug Profile | 290 | 4 |
| OSU-2S Drug Profile | 294 | 1 |
| PATLM-1 Drug Profile | 295 | 2 |
| PCAR-019 Drug Profile | 297 | 1 |
| pembrolizumab Drug Profile | 298 | 31 |
| ramucirumab Drug Profile | 329 | 10 |
| ribociclib succinate Drug Profile | 339 | 5 |
| S-055746 Drug Profile | 344 | 1 |
| sapanisertib Drug Profile | 345 | 3 |
| SEL-120 Drug Profile | 348 | 2 |
| SEL-12034 Drug Profile | 350 | 2 |
| SEL-24B489 Drug Profile | 352 | 1 |
| selinexor Drug Profile | 353 | 17 |
| SGN-CD70A Drug Profile | 370 | 1 |
| SL-101 Drug Profile | 371 | 1 |
| spebrutinib besylate Drug Profile | 372 | 2 |
| TAK-659 Drug Profile | 374 | 1 |
| TGR-1202 Drug Profile | 375 | 7 |
| tisagenlecleucel-T Drug Profile | 382 | 5 |
| tretinoin Drug Profile | 387 | 1 |
| ublituximab Drug Profile | 388 | 7 |
| UC-961 Drug Profile | 395 | 2 |
| venetoclax Drug Profile | 397 | 9 |
| VLX-1570 Drug Profile | 406 | 2 |
| vorinostat Drug Profile | 408 | 4 |
| Mantle Cell Lymphoma Dormant Projects | 412 | 3 |
| Mantle Cell Lymphoma Discontinued Products | 415 | 1 |
| Mantle Cell Lymphoma Product Development Milestones | 416 | 9 |
| Featured News &Press Releases | 416 | 1 |
| Jul 21, 2016: CHMP adopts extension to existing therapeutic indication for Imbruvica | 416 | 1 |
| Jun 06, 2016: MorphoSys Presents Updated Clinical Data for MOR208 in Non-Hodgkins Lymphoma at ASCO 2016 | 416 | 1 |
| Jun 06, 2016: Nature publication on the anti-cancer mode-of-action of VLX1570 | 417 | 1 |
| May 02, 2016: Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications | 418 | 1 |
| Apr 13, 2016: TG Therapeutics Announces Issuance of Composition of Matter Patent for TG-1101 in the United States | 418 | 1 |
| Mar 09, 2016: Genmab Achieves Second Milestone in Daratumumab NHL Study Under Collaboration with Janssen | 419 | 1 |
| Feb 25, 2016: Acalabrutinib recommended for orphan drug designation in Europe for three indications | 419 | 1 |
| Dec 24, 2015: SymBio Files Supplemental NDA for TREAKISYM in a 25mg Vial (Different Strength) | 420 | 1 |
| Dec 24, 2015: SymBio Files Supplemental NDA for TREAKISYM in First-Line Low-grade NHL and MCL | 420 | 1 |
| Dec 07, 2015: Imbruvica (Ibrutinib) Phase 3 Ray Data Show Significant Reductions in Disease Progression Versus Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma Patients | 420 | 1 |
| Dec 07, 2015: TG Therapeutics Announces Oral Presentation of Novel Pre-Clinical Combinations With TGR-1202 by Investigators at Columbia University at the 57th American Society of Hematology Annual Meeting | 421 | 1 |
| Dec 07, 2015: TG Therapeutics Announces Data Presentation for TG-1101 in Combination With Ibrutinib at the 57th American Society of Hematology Annual Meeting | 422 | 1 |
| Nov 30, 2015: New Data from Bayer s Portfolio in Oncology to be Presented at ASH 2015 | 423 | 1 |
| Nov 19, 2015: The Mayo Clinic publishes new data on Vivolux drug candidate VLX 1570 in Ibrutinib-Resistant Mantle Cell Lymphoma at the ash 57th annual conference, Orlando, Florida | 423 | 1 |
| Nov 09, 2015: Kite Pharma Initiates Phase 2 Clinical Study of KTE-C19 in Patients With Relapsed or Refractory Mantle Cell Lymphoma to Support Registration for a Second Indication | 424 | 1 |
| Appendix | 425 | 2 |
| Methodology | 425 | 1 |
| Coverage | 425 | 1 |
| Secondary Research | 425 | 1 |
| Primary Research | 425 | 1 |
| Expert Panel Validation | 425 | 1 |
| Contact Us | 425 | 1 |
| Disclaimer | 426 | 1 |